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INTRODUCTION:  Fluoxetine  is a selective  serotonin  reuptake  inhibitor  (SSRI)  that is safely  used  for  treat-
ment  of  psychosomatic  disorders.  Despite  being  associated  with  a low  side effect  proﬁle,  it has  been
reported  to cause  hematological  side effects  including  vaginal  bleeding,  epistaxis,  purpura,  hematuria,
intracranial  bleeding,  and  rectal  bleeding.  Isolated  breast  ecchymosis  is one  of  exceedingly  rare  SSRI-
induced  hematological  abnormalities.
PRESENTATION OF  CASE:  In this  case study,  we  report  a case  of  left breast  ecchymosis  in a  75-year-old
woman  that  developed  in conjunction  with  use of the  SSRI  ﬂuoxetine.
DISCUSSION: The  use of SSRIs  has  surged  over  the  past  decades  due  to  increased  diagnosis  and  focus
on  clinical  management  of  depression  and  anxiety  disorders,  especially  in  developed  nations.  The  low
side  effect  proﬁles  of  the  eight  currently  marketed  SSRI  agents  has further  promoted  their use  in  the
general  population.  While  the  most  commonly  reported  side  effects  are mild and  relatively  tolerable,  a
risk  of SSRI-related  abnormal  bleeding  exists  and  may  represent  a life-threatening  side  effect.  The most
frequent  SSRI-related  bleeding  manifestation  is  ecchymosis,  but  cases  of  isolated  breast  ecchymosis  are
exceedingly  rare and  to date  only  one  report  of  SSRI-induced  breast  ecchymosis  is included  in the  publicly
available  literature.
CONCLUSION:  Three  factors  may  have  played  a role  in lack  of  reports  describing  SSRI-induced  breast
ecchymosis  in literature.  First,  SSRIs  indeed  very  seldom  cause  breast  ecchymosis;  second,  physicians  are
not  aware  of  such  a  causal  relationship;  and  third,  physicians  ﬁnd  this  side  effect  not  worth  to  publish.
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. Introduction
The selective serotonin reuptake inhibitor (SSRI) ﬂuoxetine has
 well-established history of safe clinical application as a treat-
ent of psychosomatic disorders, such as depression, anxiety, and
bsessive-compulsive disorder.1,2 However, despite the low side
ffect proﬁle associated with all SSRIs, cases of drug-related hema-
ological side effects are not infrequent and the most common
anifestations include vaginal bleeding, epistaxis, purpura, hema-
uria, intracranial bleeding, and rectal bleeding.1–5 To date, only
ne report of SSRI (sertraline)-induced breast ecchymosis has been
Open access under CC BY-NC-Nublished in the publicly available literature,1 suggesting that this
ay  be an exceedingly rare manifestation. Here, we report a case
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of left breast ecchymosis that developed in a 75-year-old woman
in conjunction with ﬂuoxetine usage.
2. Case report
A  75-year-old female presented to our clinic for investigation of
unexplained painful swelling and visible bruising of the left breast
(Fig. 1). Upon physical examination, nearly 75% of the affected
breast was  found to be ecchymotic and slightly tender to touch,
but no palpable mass was detected. The patient denied experienc-
ing any physical trauma event that may  have caused the symptoms.
All results of routine laboratory testing, including complete blood
count, liver and kidney function assays and the coagulation panel
assay, were within normal ranges. Bilateral whole-breast ultra-
sonography revealed subcutaneous edema in the left breast, but
no signs of abscess or hematoma. The patient’s medical history
was unremarkable, except for a diagnosis of depression and ongo-
ing prescription for ﬂuoxetine. The patient reported adhering to
the prescribed dosing of 40 mg/day using the Fluoxetine (Prozac,
se.Eli Lilly, Indianapolis, IN, USA) and occasionally supplementing
the regimen at bedtime with 2 mg/mL  Norodol, taken in droplet
form (Haloperidol; Ali Raif Ilac, Istanbul, Turkey). Based on the my
previous experience with SSRI-induced ecchymosis, the ﬂuoxetine
s Ltd. Open access under CC BY-NC-ND license.
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cFig. 1. Gross appearance of the ecchymosis in the left breast.
rug was immediately withdrawn and replaced with a tricyclic
ntidepressant, topical chondroitin polysulphate (Hirudoid Forte
rème; Santa Farma, Istanbul, Turkey), and a non-steroidal anti-
nﬂammatory drug (Etol Fort 400 mg,  Nobel, Umraniye, Turkey).
t the 10-day follow-up, physical examination revealed that the
cchymotic region had reduced in size appreciably. At the 20-day
ollow-up, the ecchymosis was completely resolved.
. Discussion
SSRIs are the most commonly prescribed pharmacologic agents
or clinical treatment of psychiatric disorders.5 The mild side effect
roﬁle is generally tolerable and many patients remain on the
rescribed regimen for years.4,5 However, the potentially more
evere side effect of bleeding remains a considerable risk of all cur-
ently marketed SSRIs.1–3,5 The molecular mechanisms underlying
hese hematological side effects involve the peripheral actions of
erotonin1,2 particularly disruptions in the otherwise normal pro-
esses of thrombocyte aggregation and vascular smooth muscle
onus.1 SSRIs inhibit serotonin re-uptake and decrease the amount
f stored serotonin in thrombocytes, which reduces thrombocyte
ggregation and leads to the bleeding tendency in patients using
hese drugs.1,5
Diagnosis of an SSRI-induced hematological side effect can
nly be made after exclude the possibility of an underlying func-
ional thrombocyte disorder. Speciﬁcally, all tests of thrombocyte
unctions tests and clotting factor deﬁciency factors (i.e. bleed-
ng time, clotting time, prothrombin time, and INR) should show
esults within normal limits. The normal laboratory tests of the
atient described herein led to the suspicion of SSRI-induced iso-
ated ecchymosis of the breast. This case, while rare, highlights
he importance of considering ﬂuoxetine-induced bleeding diathe-
is in patients with a history of ﬂuoxetine use as antidepressant
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therapy, no history of trauma or use of antiplatelet agents, and
entirely normal bleeding parameters.
SSRI-induced breast ecchymosis may  be similar to the ecchy-
motic lesions that develop in other parts of the body in response to
serotonin inhibition. However, the extreme rarity of case reports
describing isolated breast ecchymosis secondary to SSRI use limit
our ability to understand the particular risks and mechanisms
of this particular hematological side effect. It is possible that
SSRIs very seldom cause breast ecchymosis, or that cases are
underreported because physicians are not aware of such a causal
relationship; it is also possible that the side effect is self-limiting
or so mild that patients and physicians disregard it. Nevertheless,
the mere lack in understanding the etiology of such rare cases of
SSRI-induced breast ecchymosis merit their inclusion in the pub-
licly available literature, as they may  help to increase awareness
and knowledge of risks involved with SSRIs.
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